Literature DB >> 2688539

An investigation of the properties and possible clinical significance of the lysosomal alpha-glucosidase GAA*2 allele.

D M Swallow1, M Kroos, A T Van der Ploeg, B Griffiths, I Islam, C B Marenah, A J Reuser.   

Abstract

Properties of the acid alpha-glucosidase, GAA2, the product of the GAA*2 allele have been compared with those of the common allele product GAA1, GAA2 has an altered affinity for glycogen but resembles GAA1 in its affinity for low molecular weight substrates, and also in its processing, as judged by immunoblot analysis of the denatured polypeptides. Starch gel electrophoretic analysis of fibroblasts from 15 patients with late onset glycogen storage disease type II (GSDII) failed to reveal either homozygotes or heterozygotes for the GAA*2 allele (GAA2-2 or GAA2-0) providing evidence that neither of these genotypes lead to late onset GSDII despite the impaired activity of the enzyme towards glycogen.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2688539     DOI: 10.1111/j.1469-1809.1989.tb01782.x

Source DB:  PubMed          Journal:  Ann Hum Genet        ISSN: 0003-4800            Impact factor:   1.670


  9 in total

1.  Seven cases of Pompe disease from Greece.

Authors:  M Kroos; P Manta; I Mavridou; F Muntoni; D Halley; R Van der Helm; D Zaifeiriou; A Van der Ploeg; A Reuser; H Michelakakis
Journal:  J Inherit Metab Dis       Date:  2006-08       Impact factor: 4.982

2.  Gene-specific features enhance interpretation of mutational impact on acid α-glucosidase enzyme activity.

Authors:  Aashish N Adhikari
Journal:  Hum Mutat       Date:  2019-08-07       Impact factor: 4.878

3.  Enzyme analysis for Pompe disease in leukocytes; superior results with natural substrate compared with artificial substrates.

Authors:  O P van Diggelen; L F Oemardien; N A M E van der Beek; M A Kroos; H K Wind; Y V Voznyi; D Burke; M Jackson; B G Winchester; A J J Reuser
Journal:  J Inherit Metab Dis       Date:  2009-04-19       Impact factor: 4.982

Review 4.  Acid alpha-glucosidase deficiency (Pompe disease).

Authors:  Tokiko Fukuda; Ashley Roberts; Paul H Plotz; Nina Raben
Journal:  Curr Neurol Neurosci Rep       Date:  2007-01       Impact factor: 5.081

5.  Adult and infantile glycogenosis type II in one family, explained by allelic diversity.

Authors:  L H Hoefsloot; A T van der Ploeg; M A Kroos; M Hoogeveen-Westerveld; B A Oostra; A J Reuser
Journal:  Am J Hum Genet       Date:  1990-01       Impact factor: 11.025

6.  Identification of the base-pair substitution responsible for a human acid alpha glucosidase allele with lower "affinity" for glycogen (GAA 2) and transient gene expression in deficient cells.

Authors:  F Martiniuk; M Bodkin; S Tzall; R Hirschhorn
Journal:  Am J Hum Genet       Date:  1990-09       Impact factor: 11.025

7.  GAA variants and phenotypes among 1,079 patients with Pompe disease: Data from the Pompe Registry.

Authors:  Arnold J J Reuser; Ans T van der Ploeg; Yin-Hsiu Chien; Juan Llerena; Mary-Alice Abbott; Paula R Clemens; Virginia E Kimonis; Nancy Leslie; Sonia S Maruti; Bernd-Jan Sanson; Roberto Araujo; Magali Periquet; Antonio Toscano; Priya S Kishnani
Journal:  Hum Mutat       Date:  2019-08-07       Impact factor: 4.878

8.  Extension of the Pompe mutation database by linking disease-associated variants to clinical severity.

Authors:  Monica Y Niño; Stijn L M In 't Groen; Atze J Bergsma; Nadine A M E van der Beek; Marian Kroos; Marianne Hoogeveen-Westerveld; Ans T van der Ploeg; W W M Pim Pijnappel
Journal:  Hum Mutat       Date:  2019-07-29       Impact factor: 4.878

9.  Whole-exome sequencing of the mummified remains of Cangrande della Scala (1291-1329 CE) indicates the first known case of late-onset Pompe disease.

Authors:  Barbara Iadarola; Denise Lavezzari; Alessandra Modi; Chiara Degli Esposti; Cristina Beltrami; Marzia Rossato; Valentina Zaro; Ettore Napione; Leonardo Latella; Martina Lari; David Caramelli; Alessandro Salviati; Massimo Delledonne
Journal:  Sci Rep       Date:  2021-10-26       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.